Pharma-Bio Serv Q3 net income up $0.2M to $0.5M; revenue down $0.2M to $4.6M

Pharma-Bio Serv, Inc.

Net income for Q3 FY2023 (three months ended July 31) was approx $0.5M, up from $0.3M YoY; nine-month net income $1.4M vs $0.9M.
Q3 revenue $4.6M, down from $4.8M YoY; nine-month revenue $13.4M vs $14.8M.
Gross profit margin improved 6.4 percentage points in Q3 and 5.3 percentage points YTD.
CEO Sanchez highlighted successful strategy, new market expansion, and leveraging FDA scrutiny for profitability.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Pharma-Bio Serv, Inc. reported financial results for the three and nine months ended July 31, 2023.

Period: the three and nine months ended July 31, 2023
Result: reported results

Exact text from the filing

On September 14, 2023, Pharma-Bio Serv, Inc. (the “Company”) issued a press release announcing its results of operations for the three and nine months ended July 31, 2023.

View on SEC.gov

308 earnings releases filed in the last 30 days. Browse all earnings releases →

Pharma-Bio Serv, Inc. filing history →

Source: SEC EDGAR

accession 0001654954-23-011895

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.